Benda Pharmaceutical Inc. (BPMA.OB)

All Comments on BPMA.OB

  • commenter
    SeekingAlpha
    Editors
    Apr 06 05:21 AM
    My Website
    General Discussion on BPMA.OB
    Is this a buy or a sell? Reply
  • commenter
    chinsag
    Jan 11 10:38 AM
    China's Economy: A Whole Different Story [view article]
    You missed FMCN imitator ILVL.OB. Have fun with that one! Reply
  • commenter
    china_stock_
    investor
    Nov 22 12:08 PM
    Another Lesson In Caution for Investors in Chinese OTC Companies [view article]
    EPS is a calcuation of net income divided by Weighted Average Common Share Outstanding (WACSO).

    Given that some of these companies have only been public for a little more than one year, the WACSO figures are skewed by the WACSO figure when these companies were still shell companies.

    For example:

    1. CYXI filed a 8K to go public on May 2006. Its post reverse split common share total is 33.6 million and was effected in July 2006.

    CYXI had net income of 1.7 million in 3rd quarter 2007 vs. 2.9 million in 3rd quarter 2006 (of which 2.2 million was due to a tax benefit provision). Normalized, income from operations for Q3 2007 was 1.7 million vs. 0.7 million in Q3 2006.

    WACSO for the 3rd quarter 2007 was 40,309,204. For the 3rd quarter 2006 WACSO was 11,418,877.

    2. CDSG filed a 8K to go public on November 2006. Its post reverse split common share total is 31.5 million and was effected in March 2007.

    CDSG had net income of 22.6 million in 3rd quarter 2007 vs. 3.1 million in 3rd quarter 2006.

    Normalizing both figures for tax, income from operations for Q3 2007 was 4.8 million vs. 4.6 million in Q3 2006.

    WASCO for Q3 2007 was 31.5 million vs. 8.1 million for Q3 2006 (when it still reflected the financials of the shell company)


     Reply
  • commenter
    jturano7423
    Apr 10 10:28 AM
    Biotech Day In Review: Agilent Buys Stratagene For $245.5 Million [view article]
    SEEKING THIRD PARTY OPINION FROM ASTUTE INVESTOR, WHO HAS THE KNOWLEDGE,COURAGE AND GUTS TO EITHER CONCUR OR DISAGREE WITH THE FOLLOWING: IT IS IN MY OPINION THAT INVESTING IN 'NSTK' NOW IS NOT THE BEST THING TO DO WITH YOUR MONEY.
    TWO YEARS AWAY FROM APPROVAL,IF APPROVED,POOR RATINGS,POOR FUNDAMENTALS,POOR MANAGEMENTS ABILITY TO TURN COMPANY AROUND, POOR EARNING REPORTS SCHEDULED FOR MAY REGARDING MARCH 2007 AND THE SAME FOR DECEMBER 2007. HAVING SAID THAT, THERE IS NO MOMENTUM, AND NO REASON FOR THE STOCK PRICE TO APPRECIATE IN THE COMING MONTHS AHEAD. SO ISN'T WISE TO INVEST IN OTHER POTENTIAL BIOTECH STOCKS IN THE MEANTIME? AM I RIGHT OR WRONG?
    JT     Reply
Loading...
Symbols:
Authors:
Quick Links: